Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Company also anticipates that it will receive final SFDA approval for the production of Felodipine sustained release tablets by December 2009, which is expected to have gross margins of approximately 85%.
Coooooooooooooool
Anyone going to listen to / participate in the conference call?
To read the 10K in PDF format:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=jgbo
then click tab "filings", there you can choose excel, pdf, html, etc
Who the F*** cares about that "unamortized debt discount", I don't even know what it means, so I won't care...
Great summary Ericteg, I've just read that page F-21 myself and it explains the whole thing.
Let's focus on the fundamentals. I find the strongest one the $104 million in cash. They can repay those debts anytime, easily and still have 104 - 35 = 69 million cash left !!!
Stuff to read on this matter:
http://www.epcc.edu/Portals/256/pdf/Acnt2304/DilutedEPS.pdf
http://accountinginfo.com/study/fs/eps-01.htm
http://www.investopedia.com/exam-guide/cfa-level-1/financial-ratios/basic-diluted-eps.asp?viewed=1
Or else maybe someone could ask during the tomorrow's CC...
But that is just our problem, the diluted number isn't being ignored and that prevents the shareprice from climbing much higher.
$104 million in cash ?!?!
There are three nasdaq markets we could uplist to. These are:
Nasdaq Global Select
Nasdaq Global Market
Nasdaq Capital Market
The first is considered the "best" because companies have to meet the highest standards of the three different markets.
Read here:
http://files.shareholder.com/downloads/NDAQ/0x0x31401/03F1D777-B1FD-446E-B3AA-3B530840062B/NASDAQ_Global_Select_Fact_sheet.pdf
As you can guess JGBO will meet all the criteria to be listed on the Nasdaq Global Select as far as I can tell.
Read page 1 of this document:
http://www.nasdaq.com/about/nasdaq_listing_req_fees.pdf
and you will see that we can list under standard 1 for the Nasdaq Global Select Market.
Let's see if this will be reality soon. We'll know more tomorrow after the CC.
Bye bye $11, I hope we`ll never see you again!
Jiangbo will be presenting at the 2009 China Growth Conference (by Brean Murray Carret), it will be held on Nov. 19 & 20th 2009
http://www.meetmax.com/sched/event_4423/~public/conference_companies.html?event_id=4423
Nice volume, nice pps: what do the buyers know that we don't know yet ?!
Uplisting perhaps? Positive surprise in the Q4 results?
Mr. Cao will be hosting, he is the big boss, so does that mean they finally will be announcing uplisting?
Thanks for sharing Bigplay777. We need something positive every now and then to keep the faith.
Maybe because: operating income will be 40-43 million and net income then could be 25 million ?
@Glen and Drexion: Well if that's the case then I'll just have to hold on to my shares until after the conversion of debentures and warrants (2011-2013 I believe). We'll see where we will be heading after that. Patience is a virtue.
Don't worry eventually the numbers will be out.
Uplisting is less certain...why wasn't it mentioned during the Rodman and Renshaw conference?
or wasn't it mentioned because the company thinks everybody knows uplisting is in the making and it doesn't help mentioning it over and over again?
As always: time will tell.
Is it my imagination or is friday always a very boring day as it comes to trading in our beloved stock?
Next week or the week after that will be different...
@ericteg: I believe the total financing was 30+5=35 million, conversion price is $8. That would mean 4+ million extra shares if the loan ever got converted. Already outstanding 11.1 million. Then add a few extra for interest that has to be repaid and that brings us to approx. 17 million fully diluted. But I am the second to admit that I don't 100% understand these convertible debentures and how they work.... We need a financial expert here.
I've noticed a few things that might be worth writing down here:
- Outstanding shares have went slightly up to 11.1 million.
- Approximately 17 traditional chinese medicines to start selling in May 2010
- JGBO tries to get as much of their products on the reimbursement list
- Management focuses on shareholder value (a little work to be done then)
- Working together with 3 institutions (for example: Shandong University)
- Operating at 70% of manufacturing capacity, in near future possible expanding (will need capital for that)
- Fully diluted 17 million shares outstanding
- Radix Dispersible Tablets growing very rapidly
- Big potential: Kang Gu Sui Yan Pian
- 3 drugs still pending final SFDA approval
- LFAA still undergoing tests and still under negotiation to acquire
- Distribution, marketing, selling throughout almost the complete country
- 11 Products from Hongrui portfolio will be introduced in phase 1
- Possible in the future: buy new products, acquire other company(s), focussing on high margin products
- Net profit margin 20.2% (Q3 2009)
Unfortunately nothing said about uplisting and/or share buyback (I find this very disturbing).
There was a little talk about the private placements (Pope and Ardsley) but I couldn't make much of it (listen to it yourself fast forward to 21 minutes or so).
Explanation on the national list of products to be reimbursed, couldn't make much of it either.
Looking at expanding into other countries. Regulations and other difficulties make it a future project.
I see I have written down a lot of things that Bigplay777 already has, hadn't read his post when I wrote this...
It is a presentation with sheets they have put online. As far as I can tell nothing really special or new. Strange they don't even mention uplisting, or haven't I read it carefull enough?
You can read it yourself: http://www.wsw.com/webcast/rrshq15/jgbo.ob/
Haven't listened to the audio yet.
Why is it so quiet here? Are you all attending the Rodman and Renshaw conference?
I`ll listen to the webcast tomorrow...
Haven`t seen that in ages: all the trades so far on the same price: $11.60,
next stop 16.10 (2009)
then up to 61.10 (2014?)
From our fellow-poster here, Glen Bradford, a nice article on the website TheStreet.com:
http://www.thestreet.com/_yahoo/story/10595957/1/stock-gems-from-asia.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Nice to see they are on track. A big positive surprise would have been even nicer. But that will probably happen when those other (20?) products of Hongrui get on the market.
Good timing to ring this PR out just before the Rodman and Renshaw conference.
Let's uplist...
I wrote a post yesterday based on the wrong info. Should have checked it but didn't, sorr, here's the link:
http://moneycentral.msn.com/investor/invsub/results/statemnt.aspx?Symbol=jgbo&stmtView=Qtr
It says revenue Q4 2008 44 million and net income 12,8 million, but as we have concluded those numbers are off.
@forzagrifo:
I see i haven't inlcuded the link in my message. Sorry. I am at work now and not able to find the link where I've found those numbers.
I think you are right on your numbers, they match with what I`ve found here:http://www.nasdaq.com/asp/ExtendFund.asp?symbol=AAPL&symbol=LTUS&symbol=JGBO&symbol=GOOG&symbol=DRGP&symbol=SUWN&symbol=DPDW&symbol=GHII&selected=JGBO
I'll see if i can reproduce my other numbers and the link.... strange...
That is one of the problems with JGBO: all over the internet different numbers. Missing info...
Eric, here is a link so you can see what JGBO made in Q4 of fiscal year 2008: 44 million, net income almost 13 million. If we assume the last Q4 is going to be just as good and we add that to the Q1, Q2, Q3 of fiscal year 2009, that makes great numbers!
Net income:
Q1 3,1 million
Q2 5,4
Q3 8,9
Q4 12,8 (assumption)
total : 30,2 milion
Divided by roughly 11 million shares and multiplied with a PE of 10, that makes a shareprice of $27.45 (non-diluted) or if we use a PE of 15: $41.18
Nice to daydream...
@ericteg: what you say about paying off the convertible debt sounds good. But how will they ever do that if they can't get their money out of China ?! So that would be the 4th item and paying off the debts would be the 5th.
I seem to remember tat the 4th quarter has been the best every year the last two years. How these analists do their math? I really don't know, I guess we have to take these estimates not too seriously...
Three steps to shareholderswealth:
Step 1: create awareness and attract investors(Rodman and Renshaw conference)
Step 2: present great annual report and ditto outlook / guidanse
Step 3: uplist
That's all there is to it! Let's go!
Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
LAIYANG, China, Sept. 2 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People’s Republic of China, today announced that Ms. Elsa Sung, the Company’s CFO will present at the upcoming Rodman & Renshaw Annual Global Investment Conference to be held on September 9-11 at the New York Palace Hotel in New York City.
The date, time and location of Jiangbo Pharmaceuticals’ presentation at the conference are as follows:
Date: Wednesday, September 9, 2009
Time: 5:20 p.m. Eastern Time
Venue: Kennedy I Salon, 4th Floor
New York Palace Hotel
455 Madison Avenue
New York, NY 10022
Webcast: http://www.wsw.com/webcast/rrshq15/jgbo.ob
A replay of the presentation will be available for 90 days following the live presentation using the same link and will also be available on the Company’s website at http://www.jiangbopharma.com.
During the conference, the Company will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with Jiangbo Pharmaceuticals’ management may contact mwoodson@rodm.com or call (212) 430-1782. Participation in the Rodman and Renshaw Annual Global Investment Conference is by invitation only.
About Rodman & Renshaw, LLC
Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People’s Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-727-8435
Email: elsasung@jiangbo.com
Web: http://www.jiangbopharma.com
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.
-0- 09/02/2009
/CONTACT: Elsa Sung, CFO of Jiangbo Pharmaceuticals, Inc.,
+1-954-727-8435, elsasung@jiangbo.com; Or Crocker Coulson, President of CCG Investor Relations, Inc., +1-646-213-1915, crocker.coulson@ccgir.com/
/Web site: http://www.jiangbopharma.com
http://www.wsw.com/webcast/rrshq15/jgbo.ob /
(JGBO)
It`s time we step up to nasdaq and get noticed. Bring out the news!
By the way, this is a nice earnings-prediction for fiscal year 2010:
http://moneycentral.msn.com/investor/invsub/analyst/earnest.asp?Symbol=JGBO
Yep, you're reading correctly: $2+. Multiply that with a cautious PE of 10 if we're uplisted and that gives an expected pps f $20+
That makes me a little more patient...
... or a total lack of interest
(temporarily)
We'll know for sure within a month or so...
Bigplay, I think we do not own enough shares too impress Mr Cao. I own some more than _bbb_ and a lot less than you have... Maybe the others can make our numbers count
Better than sending another mail maybe someone who speaks english could call in at the next conference call and ask some questions? The most important ones would be these (in my opinion):
1. What is the status of the drugs mentioned in last summers 10Q? 4Q 2009 is done and those drugs have not been SFDA approved.
2. What is happening with LFAA drug? Is it through Phase III clinical trials? Has GNPH negotiated a final purchase price?
3. What is the normal time frame to have a drug reviewed by SFDA? For the FDA in the USA, a review of a new drug application takes roughly 18 months.
4. How many shares have already been bought back as announced in the 2 million dollar share-buyback program?
5. Can you give an actual number on shares that are held by insiders, Pope, Ardsley?
6. How many shares of GHII and LTUS does GNPH still own? Are there plans on sellig these?
7. What has happened to the once promised dividend for the pre-merger US shareholders? Can this be cancelled without any consequences?
8. Are there any new drugs in development besides the three in the pipeline and the LFAA? Or is GNPH first going to concentrate on those total four and the drugs acquired with the acquisition of Hongrui?
9. Can we expect more acquisitions or a merger within a year from now?
10. Is transfering money out of the PRC to the US still an issue? Will it be resolved in the near future? How will you be paying interest or repaying debentures if you can't transfer the money?
11. Are you considering paying a dividend to all shareholders ?(not as in question 9).
I must admit I think it is a bad sign they haven't replied to our mails in a serious matter. But on the other hand our mails could have ended up in a spam-filter or whatever....
But then again time will tell.
Resending the questions through mail doesn't seem logic. Crocker gave a very shorta answer, Ms Sung didn't give an answer at all. Furthermore I am not going to resend it, maybe someone who writes better english? Or better yet these questions should be asked during a Conference Call... we'll see who picks up this task.
@_bbb_: here is the post that lists the questions, a few of them are not important anymore (nr. 1 and 2)
Most urgent to be answered I would think would be nr. 13.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37683819
@LV: Let's hope that dream comes true . . .
Bigplay777, still no word from Ms. Sung?
Then buy some shares so you can make a profit. It will surely reach $ 0.40 (pre-merger) now $ 16 again, don't you think? So here is a nice opportunity: $10 > $16 = 60% ! And that within a few months...